Global Survey Discovers Many People Are Self-Medicating with Psychedelics

March 15, 2021 13:49:00

survey conducted recently that includes 110,000 individuals who answered various questions that focused on their use of drugs, found that roughly 6% of them used psychedelics to deal with their mental health issues and emotional issues. The survey found that the drugs most commonly used by the percentage which represented about 6,500 individuals, were ketaminepsilocybinMDMA and LSD.

The Global Drug Survey 2020 included examples of people microdosing on psilocybin mushrooms or LSD on their own, as well as instances where psychedelics were consumed in a way that was unregulated but under the keen eye of another individual. The supervisors in question were found to mostly be partners or friends of the individual using the recreational drug. The report also included other settings such as traditional healing groups and psychedelic retreats.

Of the individuals who admitted to having used these recreational substances to help manage mental health issues, 2% were nonbinary, 25% were women and 72% were men.

RMIT University’s Dr. Monica Barratt stated in an interview that suppressed demand for these psychedelic substances around the globe may end up being fulfilled outside a medical setting.

The survey found that these substances were mostly used as a result of depression, anxiety or relationship issues. However, bereavement, substance use and post-traumatic stress disorder were also cited as reasons for use.

The report’s authors stated that these individuals turned to these psychedelics to manage common mental health issues that other individuals presently sought help for in conventional medical services. They noted that the report’s findings suggested that there are many individuals with common preexisting conditions for whom the current treatment methods were either unattractive, unappealing or inadequate in producing the desired results.

Survey respondents also admitted that using LSD helped enhance their well-being, with 52% of those who ingested the psychedelic reporting that enhanced well-being as their primary reason for consuming the substance. Another major reason was assistance in having to deal with a particular concern or worry.

Improving well-being was also the primary reason for responders who admitted to using psilocybin mushrooms, while other reasons were cited as obtaining a break from a psychiatric condition and dealing with worries. Of the responders who admitted to using psychedelics as a self-treatment method, 4% admitted to also visiting the emergency room.

The report’s authors also noted that the longer the wait was to launch these treatments through clinical services, the greater the risk that vulnerable individuals would be tempted to obtain these drugs in situations that carried possible greater risk of harm.

The push to change the legal status of psychedelics is being aided by many companies that are hard at work developing medicines from these substances. One of those companies is Pure Extracts Technologies Corp. (CSE: PULL) (OTC: PRXTF), which is leveraging its experience in the marijuana extracts segment and branching out into the psychedelics and functional mushrooms space.

NOTE TO INVESTORS: The latest news and updates relating to Pure Extracts Technologies Corp. (CSE: PULL) (OTC: PRXTF) are available in the company’s newsroom at

About PsychedelicNewsWire

PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.

To receive instant SMS alerts, text “Groovy” to 21000 (U.S. Mobile Phones Only)

For more information please visit

Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published:

Do you have questions or are you interested in working with PNW? Ask our Editor

PsychedelicNewsWire (PNW)
San Francisco, California
415.949.5050 Office

PsychedelicNewsWire is part of the InvestorBrandNetwork.